Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 31, 2012
Last updated: May 31, 2013
Last verified: May 2013

All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study.

In this study, researchers will try to find answers to these questions:

  • How much (if any) hepatitis C virus is in your blood after stopping your Idenix study drug?
  • Is your hepatitis C virus possibly resistant to treatment with the Idenix study drug or similar drugs?

Hepatitis C

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Durability of Sustained viral response [SVR] [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
    To evaluate the durability of sustained virological response (SVR). Plasma HCV RNA levels will be monitored over time.

Secondary Outcome Measures:
  • Kinetics of resistant variants [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
    To describe the kinetics of resistant variants to Idenix direct acting antivirals (DAAs) by HCV RNA sequencing. The presence of each identified resistant variant in the viral population will be descriptively evaluated until the viral population consists entirely of wild-type virus or over a period of 3 years, whichever comes first.

Biospecimen Retention:   Samples Without DNA

Human plasma

Estimated Enrollment: 183
Study Start Date: October 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Detailed Description:

The data obtained from this study will be used to further understand the long-term efficacy of Idenix DAAs used to treat HCV infection and to further understand HCV resistance to Idenix DAAs.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The population will include subjects who participated in studies of Idenix anti-HCV DAAs.


Inclusion Criteria:

  • Read and signed the written informed consent form (ICF) after the nature of the study has been fully explained
  • Have participated in an Idenix-sponsored study of an Idenix DAA
  • Received at least 3 consecutive days of DAA treatment in an Idenix-sponsored study
  • Agreed to comply with the visit schedule and laboratory tests

Exclusion Criteria:

  • Treatment with placebo only, in an Idenix sponsored study
  • Antiviral treatment for HCV after participation in an Idenix sponsored study of an Idenix DAA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01721265

Contact: John Z Sullivan-Bolyai, MD, MPH 1877-433-6491

United States, Kansas
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01721265     History of Changes
Other Study ID Numbers: IDX-03YF
Study First Received: October 31, 2012
Last Updated: May 31, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Hepatitis C

Additional relevant MeSH terms:
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases processed this record on November 24, 2014